Angiex selected ZingPR to generate excitement and build momentum for the Phase 1 clinical trial of AGX101, a novel antibody-drug conjugate (ADC) designed to revolutionize cancer treatment by targeting tumor blood vessels. The campaign played a crucial role in communicating the potential of AGX101 to transform cancer treatment and attracting support for Angiex's mission.